Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis: Oxaliplatin in neoadjuvant treatment for rectal cancer

BACKGROUND: Neoadjuvant fluoropirimidine (5FU)-based chemoradiotherapy (CRT) has been considered the standard of care for locally advanced rectal cancer (LARC). Whether addition of oxaliplatin (OXP) will further improve clinical outcomes is still debated. We conducted a meta-analysis to evaluate the...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:BMC Cancer
Huvudupphovsmän: De Felice, Francesca, Benevento, Ilaria, Magnante, Anna Lisa, Musio, Daniela, Bulzonetti, Nadia, Caiazzo, Rossella, Tombolini, Vincenzo
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2017
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5427623/
https://ncbi.nlm.nih.gov/pubmed/28499428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3323-4
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk